Xenon Pharmaceuticals (XENE) Return on Capital Employed (2014 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Return on Capital Employed of 42.53% for Q1 2026, down 287.0% year-over-year from 22.75% in Q1 2025, and up 34.02% quarter-over-quarter from 64.47% in Q4 2025.
Xenon Pharmaceuticals (XENE) Return on Capital Employed (2014 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Return on Capital Employed for 13 consecutive years, with 42.53% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 287.0% year-over-year to 42.53%; the TTM figure through Mar 2026 stood at 42.53% (down 287.0% YoY), while the FY2025 annual figure was 55.36%, down 2234.0% from the prior year.
- Return on Capital Employed grew to 42.53% in Q1 2026 per XENE's latest filing, from 64.47% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 13.17% in Q2 2022 and bottomed at 64.47% in Q4 2025.
- Historically, Return on Capital Employed has averaged 31.53% across 5 years, with a median of 27.61% in 2023.
- Annual changes were most pronounced in 2022 — Return on Capital Employed soared 1188 bps — and 2025, when it sank 2872 bps.
- Xenon Pharmaceuticals' Return on Capital Employed stood at 17.4% in 2022, then plunged by 56 bps to 27.07% in 2023, then slumped by 32 bps to 35.74% in 2024, then slumped by 80 bps to 64.47% in 2025, then surged by 34 bps to 42.53% in 2026.
- Business Quant data shows XENE's Return on Capital Employed at 42.53% in Q1 2026, 64.47% in Q4 2025, and 56.54% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | -34.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.07% |
| Mar 31, 2026 | -42.53% |
| Dec 31, 2025 | -64.47% |
| Sep 30, 2025 | -56.54% |
| Jun 30, 2025 | -47.08% |
| Mar 31, 2025 | -39.66% |
| Dec 31, 2024 | -35.74% |
| Sep 30, 2024 | -30.78% |
| Jun 30, 2024 | -27.29% |
| Mar 31, 2024 | -24.36% |
| Dec 31, 2023 | -27.07% |
| Sep 30, 2023 | -31.18% |
| Jun 30, 2023 | -27.61% |
| Mar 31, 2023 | -22.51% |
| Dec 31, 2022 | -17.40% |
| Sep 30, 2022 | -14.26% |
| Jun 30, 2022 | -13.17% |
| Mar 31, 2022 | -14.42% |
| Dec 31, 2021 | -19.56% |
| Sep 30, 2021 | -26.13% |